+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Opium (Opioid) Addiction (Central Nervous System) - Drugs In Development, 2021

  • ID: 5402688
  • Report
  • July 2021
  • Region: Global
  • 249 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • Adial Pharmaceuticals Inc
  • BioXcel Therapeutics Inc
  • Elysium Therapeutics Inc
  • Fannin Partners LLC
  • Nirsum Laboratories Inc
  • Plumb Pharmaceuticals LLC
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Drugs In Development, 2021, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 13, 2, 34, 11 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 6 molecules, respectively.Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).- The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adial Pharmaceuticals Inc
  • BioXcel Therapeutics Inc
  • Elysium Therapeutics Inc
  • Fannin Partners LLC
  • Nirsum Laboratories Inc
  • Plumb Pharmaceuticals LLC

Introduction
Opium (Opioid) Addiction - Overview
  • Opium (Opioid) Addiction - Therapeutics Development
Opium (Opioid) Addiction - Therapeutics AssessmentOpium (Opioid) Addiction - Companies Involved in Therapeutics DevelopmentOpium (Opioid) Addiction - Drug ProfilesOpium (Opioid) Addiction - Dormant ProjectsOpium (Opioid) Addiction - Discontinued ProductsOpium (Opioid) Addiction - Product Development MilestonesAppendix
List of Tables
  • Number of Products under Development for Opium (Opioid) Addiction, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Opium (Opioid) Addiction - Pipeline by Adial Pharmaceuticals Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Alar Pharmaceuticals Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Amygdala Neurosciences Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Antheia Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Aphios Corp, 2021
  • Opium (Opioid) Addiction - Pipeline by Aquilus Pharmaceuticals Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Astellas Pharma Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Atai Life Sciences BV, 2021
  • Opium (Opioid) Addiction - Pipeline by Benuvia Therapeutics Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by BioXcel Therapeutics Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Bridge Therapeutics Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Bright Minds Biosciences Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Camurus AB, 2021
  • Opium (Opioid) Addiction - Pipeline by Cessation Therapeutics LLC, 2021
  • Opium (Opioid) Addiction - Pipeline by Closed Loop Medicine Ltd, 2021
  • Opium (Opioid) Addiction - Pipeline by Daisy Pharma Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Delpor Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by DemeRx Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by DMK Pharmaceuticals Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Elysium Therapeutics Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Emergent BioSolutions Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Ensysce Biosciences Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Eolas Therapeutics Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Epiodyne Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Ethismos Research Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Exxel Pharma Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Fab’entech SA, 2021
  • Opium (Opioid) Addiction - Pipeline by Fannin Partners LLC, 2021
  • Opium (Opioid) Addiction - Pipeline by Gilgamesh Pharmaceuticals Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Hunan Saiao Pharmaceutical Co Ltd, 2021
  • Opium (Opioid) Addiction - Pipeline by Indivior Plc, 2021
  • Opium (Opioid) Addiction - Pipeline by Inimmune Corp, 2021
  • Opium (Opioid) Addiction - Pipeline by Jazz Pharmaceuticals Plc, 2021
  • Opium (Opioid) Addiction - Pipeline by Kinoxis Therapeutics Pty Ltd, 2021
  • Opium (Opioid) Addiction - Pipeline by Lyndra Therapeutics Inc., 2021
  • Opium (Opioid) Addiction - Pipeline by Mayne Pharma Group Ltd, 2021
  • Opium (Opioid) Addiction - Pipeline by Mebias Discovery LLC, 2021
  • Opium (Opioid) Addiction - Pipeline by Mind Medicine MindMed Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Nirsum Laboratories Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Omeros Corp, 2021
  • Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Orexo AB, 2021
  • Opium (Opioid) Addiction - Pipeline by Orphomed Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Osmotica Pharmaceutical Corp, 2021
  • Opium (Opioid) Addiction - Pipeline by OYE Therapeutics Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Palisades Therapeutics, 2021
  • Opium (Opioid) Addiction - Pipeline by Pharmazz Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Phoenix PharmaLabs Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Plumb Pharmaceuticals LLC, 2021
  • Opium (Opioid) Addiction - Pipeline by Revive Therapeutics Ltd, 2021
  • Opium (Opioid) Addiction - Pipeline by SafeRX Pharmaceuticals Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Sen-Jam Pharmaceutical LLC, 2021
  • Opium (Opioid) Addiction - Pipeline by Senzer Ltd, 2021
  • Opium (Opioid) Addiction - Pipeline by Serina Therapeutics Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Syntropharma Ltd, 2021
  • Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by VDM Biochemicals Inc, 2021
  • Opium (Opioid) Addiction - Pipeline by Vivreon Biosciences LLC, 2021
  • Opium (Opioid) Addiction - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, 2021
  • Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, 2021
  • Opium (Opioid) Addiction - Dormant Projects, 2021
  • Opium (Opioid) Addiction - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Opium (Opioid) Addiction, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Adial Pharmaceuticals Inc
  • Alar Pharmaceuticals Inc
  • Amygdala Neurosciences Inc
  • Antheia Inc
  • Aoxing Pharmaceutical Company Inc
  • Aphios Corp
  • Aquilus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Atai Life Sciences BV
  • Benuvia Therapeutics Inc
  • BioCorRx Inc
  • BioXcel Therapeutics Inc
  • Bridge Therapeutics Inc
  • Bright Minds Biosciences Inc
  • Camurus AB
  • Cessation Therapeutics LLC
  • Closed Loop Medicine Ltd
  • Daisy Pharma Inc
  • Delpor Inc
  • DemeRx Inc
  • DMK Pharmaceuticals Inc
  • Elysium Therapeutics Inc
  • Emergent BioSolutions Inc
  • Ensysce Biosciences Inc
  • Eolas Therapeutics Inc
  • Epiodyne Inc
  • Ethismos Research Inc
  • Exxel Pharma Inc
  • Fab’entech SA
  • Fannin Partners LLC
  • Gilgamesh Pharmaceuticals Inc
  • Hunan Saiao Pharmaceutical Co Ltd
  • Indivior Plc
  • Inimmune Corp
  • Jazz Pharmaceuticals Plc
  • Kinoxis Therapeutics Pty Ltd
  • Lyndra Therapeutics Inc.
  • Mayne Pharma Group Ltd
  • Mebias Discovery LLC
  • Mind Medicine MindMed Inc
  • Nirsum Laboratories Inc
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Orexo AB
  • Orphomed Inc
  • Osmotica Pharmaceutical Corp
  • OYE Therapeutics Inc
  • Palisades Therapeutics
  • Pharmazz Inc
  • Phoenix PharmaLabs Inc
  • Plumb Pharmaceuticals LLC
  • Revive Therapeutics Ltd
  • SafeRX Pharmaceuticals Inc
  • Sen-Jam Pharmaceutical LLC
  • Senzer Ltd
  • Serina Therapeutics Inc
  • Syntropharma Ltd
  • Titan Pharmaceuticals Inc
  • VDM Biochemicals Inc
  • Vivreon Biosciences LLC
  • Yichang Humanwell Pharmaceutical Co Ltd
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown